Geode Capital Management’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
DCM
ACA
DTC
OCA
CC
TECP
Geode Capital Management's DFTX Position: Q1 2026 in Review
Geode Capital Management increased its Definium Therapeutics (DFTX) stake by 7% in Q1 2026, buying an estimated $2.76M and bringing the position to 2,495,399 shares worth $47.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1522.
Geode Capital Management first reported a position in DFTX in Q2 2021 and has held it in 19 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.
- Geode Capital Management held 2,495,399 shares of Definium Therapeutics worth $47.2M as of Q1 2026.
- Geode Capital Management bought 162,461 Definium Therapeutics shares in Q1 2026, an estimated $2.76M.
- Definium Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1522 holding.
- Geode Capital Management first reported a position in Definium Therapeutics in Q2 2021 and has held it in 19 quarters since.
- 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.